Health Matters: U.S. FDA advisers endorse Alzheimer's drug

I'm Katherine Ward with your top health headlines right now. Residents of a northwest Calgary neighborhood are able to drink tap water again without boiling it first. A boil water advisory was lifted Monday evening for the bonus area after a section of a major feeder main broke last week. An online update by the City of Calgary says it may changes to allow safe and clean water to bypass the damaged main to reach bonus. Alberta Health Services has declared water in the community satisfactory. A water emergency is still in effect in Calgary, with water use restrictions remaining in place citywide while crews work to replace the damaged pipe on the feeder line. That work is expected to continue over the next few days. Remember, the most optimistic scenario that we were offered on the weekend was that we might have the feeder main repaired in five to seven days. Following that, it still needs to be flushed and the water will need to be tested. That means several more days of all of us being low water users. Federal Health advisors have endorsed a closely watched Alzheimer's drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisors, the drug, donanemab, would only be the 2nd Alzheimer's drug approved to slow cognitive decline due to Alzheimer's. Despite discrepancies and how Lilly studied its drug, the panel says it should be approved broadly for various patients with the disease. The FDA approved a similar infused drug, Lakemby, last year. Cognitive exams are not a good indicator for a concussion diagnosis, according to a new study. US researchers found about half of college athletes who are ultimately diagnosed with a concussion test normally on the recommended cognitive skills test. Instead, the researchers found concussion symptoms are a better indicator, such as headache, nausea, dizziness or blurred vision. Moderna says its combination COVID-19 and influenza M RNA vaccine worked well in a late stage trial. It found the combined shot generated a stronger immune response in adults over age 50 compared to separate shots. Moderna President Stephen Hogue says the drug maker hopes to launch the combination shot for the autumn respiratory disease season in 2025. Those are the top health stories right now. For more, you can head to globalnews.ca. I'm Catherine Ward.